Custom-Built Molecule May Improve On Its Natural Counterpart
Monday, February 22, 2021
Ten years ago, a young woman from Chicago came to the National Institutes of Health with a rare genetic condition. A mutation in her DNA was making her metabolic system malfunction, causing levels of fat molecules called triglycerides in her blood to skyrocket far out of the normal range. This triggered inflammation in her pancreas, a painful and potentially life-threatening condition known as pancreatitis. She couldn’t understand why there wasn’t any kind of treatment to help her.
IRP senior investigator Alan T. Remaley, M.D., Ph.D., took on the challenge with the help of Anna Wolska, Ph.D., a research fellow in his lab. Dr. Remaley leads the Lipoprotein Metabolism Section in the National Heart, Lung, and Blood Institute (NHLBI), where he and Dr. Wolska study lipoproteins, small particles that transport fats such as cholesterol and triglycerides through the bloodstream to be broken down and used by cells for energy. Their efforts to help that young woman ultimately led to the discovery — published last January — of a new strategy for reducing triglycerides in order to treat serious ailments like pancreatitis and heart disease.
Program Boosts Initiatives Supporting Researchers Across NIH
Tuesday, September 1, 2020
From Superbowl-winning football teams to comic book cohorts like The Avengers, combining the efforts of multiple talented individuals is a proven strategy for achieving remarkable results. It may come as no surprise, then, that the NIH’s Intramural Research Program (IRP) strongly encourages collaborations that breach the boundaries of its 24 Institutes and Centers. One example of these efforts is the Director’s Challenge Innovation Awards Program, which since 2009 has funded high-impact scientific projects that bring together researchers from across the IRP.
Potential biomarker may contribute to personalized treatments
Tuesday, February 5, 2019
Until recently, medical treatment has largely been one-size-fits-all, with doctors unable to separate patients into distinct groups that might benefit more or less from a particular approach. However, researchers are increasingly finding that individuals with the same disease can differ markedly in ways that might one day influence their care. A recent IRP study has identified a particular molecule that may have just such an impact for patients with damaged lungs.